author-photo

Kerstin Kapp

41

Papers

150

Citations

Citation Trend

Filter By

Papers (30) Sort By

Journal Conference Others

Induction of tumor-specific immune responses by the TLR9 agonist EnanDIM in murine syngeneic tumor models

2019 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Combination of TLR9 agonists EnanDIM with checkpoint inhibitors for cancer immunotherapy.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 5557: EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Modulation of T cell and macrophage tumor infiltration by the TLR9 agonist lefitolimod in a murine model of colorectal cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (36)
A new family of potent TLR9 agonists, EnanDIM, which inhibit tumor growth in various syngeneic murine models

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
56PModulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Immunological and first anti-tumor data of the TLR9 agonist dSLIM2006

2017 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
TLR9 agonist lefitolimod to improve antitumor effect of checkpoint inhibitors in vivo.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)